Myriad myPlan Lung Cancer Test Met Primary Endpoint in Validation Study
October 28, 2013 at 07:07 AM EDT
Myriad Genetics (NASDAQ: MYGN ) today announced that validation data for the Myriad myPlan Lung Cancer test showed that it significantly predicted patients' risk of death from early-stage lung adenocarcinoma within five years of being diagnosed. A key finding of the validation study is that patients with a high-risk
